ライフサイエンスコーパス: clinical activity

1 tolerated dose (MTD), pharmacokinetics, and clinical activity.

2 and how disparity relates to differences in clinical activity.

3 uggests that this cytokine may have superior clinical activity.

4 ve health-care resources without sacrificing clinical activity.

5 or, to cetuximab has shown encouraging early clinical activity.

6 s, appears to be the basis for this striking clinical activity.

7 o correlate tumor molecular alterations with clinical activity.

8 tastatic melanoma has resulted in impressive clinical activity.

9 echanism of drug action that can explain its clinical activity.

10 pies that target this axis have demonstrated clinical activity.

11 important predictor of future endoscopic and clinical activity.

12 ited by present techniques for assessment of clinical activity.

13 w inhibitors of BCR signaling appear to have clinical activity.

14 VDAC and that this may play a role in their clinical activity.

15 acitidine is well tolerated with encouraging clinical activity.

16 ith different targets would have substantial clinical activity.

17 e of FcgammaRIIIA-mediated mechanisms in RTX clinical activity.

18 End points included safety/tolerability and clinical activity.

19 ese inhibitors lack significant single-agent clinical activity.

20 af and MEK inhibitors have exhibited limited clinical activity.

21 There is also early evidence of clinical activity.

22 overall survival (OS), and PD-L1-associated clinical activity.

23 cell receptor, and a tumor target have shown clinical activity.

24 f a maximum-tolerated dose and assessment of clinical activity.

25 es; secondary objectives included effects on clinical activity.

26 aseline and 6 months or when patients showed clinical activity.

27 T-cell activation, uniquely correlated with clinical activity.

28 ared between groups by anatomic location and clinical activity.

29 an additional explanation for abiraterone's clinical activity.

30 okinetics, pharmacodynamics, and preliminary clinical activity.

31 ic inhibitors targeting this axis have shown clinical activity.

32 uired to translate preclinical efficacy into clinical activity.

33 ifiers reported actual provision of specific clinical activities.

34 Platinum compounds display clinical activity against a wide variety of solid tumors

35 bumin-binding prodrug of doxorubicin, showed clinical activity against advanced soft-tissue sarcoma i

36 ed extended persistence that correlated with clinical activity against antigen-positive myeloma.

37 differentiated in vitro has shown promising clinical activity against cancer.

38 tive breast cancers but are unlikely to have clinical activity against HER-2-positive or triple-negat

39 ibitors (HA-HDIs) have shown preclinical and clinical activity against human acute leukemia.

40 ite their preclinical efficacy and promising clinical activity against late stage metastatic melanoma

41 ntly, CDK4/6 inhibitors have shown promising clinical activity against several cancer types, includin

42 ISAV was well tolerated and demonstrated clinical activity against these endemic fungi with a saf

43 In contrast, mupirocin ointment had minimal clinical activity against this USA300 strain, resulting

44 our with indolent lymphomas) had evidence of clinical activity, albeit not meeting objective response

45 ts were expected to attend 64 activities (26 clinical activities and 38 tutorial-based activities) bu

46 ogram directors, which demonstrate ranges of clinical activities and identify significant interest fo

47 mined the rate of exception reporting for 65 clinical activities and the association between this rat

48 the use of polypills in future research and clinical activities and to synthesise contemporary evide

49 e Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety pr

50 In summary, duvelisib demonstrated promising clinical activity and an acceptable safety profile in re

51 treated with sorafenib, but did demonstrate clinical activity and an acceptable safety profile.

52 Little is known about their clinical activity and collections.

53 im analysis show that venetoclax has durable clinical activity and favourable tolerability in patient

54 Brigatinib shows promising clinical activity and has an acceptable safety profile i

55 otubule inhibitor that by itself has limited clinical activity and high systemic toxicity.

56 ary end points were safety and tolerability; clinical activity and immune activation were secondary e

57 odds ratio [OR], 0.33; 95% CI, 0.15-0.70 for clinical activity and OR, 0.35; 95% CI, 0.15-0.79 for ra

58 ronment may enhance natural killer (NK) cell clinical activity and produce encouraging results in the

59 ssion profiles in patients during periods of clinical activity and quiescence, and demonstrated simil

60 linical trials of newer agents with improved clinical activity and reduced side effects in specific t

61 Clinical activity and safety of brentuximab vedotin, a C

62 ruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancie

63 We evaluated the clinical activity and tolerability of sunitinib malate (

64 ched to the antibody are key determinants of clinical activity and tolerability.

65 Oral neratinib showed substantial clinical activity and was reasonably well tolerated amon

66 Alectinib showed clinical activity and was well tolerated in patients wit

67 ositive predictive value of 67% (4 of 6) for clinical activity, and a negative predictive value of 86

68 Frequent emergency call duty, increased clinical activity, and greater perceived difference betw

69 ordination, have focused on limited areas of clinical activity, and have not been clearly linked to q

70 Periodontal disease (PD) status, clinical activity, and sociodemographic factors were det

71 Dacomitinib had encouraging clinical activity as initial systemic treatment in clini

72 HD lenalidomide has evidence of clinical activity as initial therapy for older AML patie

73 Despite there being little evidence of clinical activity as single-agent therapies, we show tha

74 tylase inhibitor romidepsin has single agent clinical activity associated with durable responses in p

75 These scientific and clinical activities, attempting to exploit the innate an

76 ncer vaccines are beginning to show signs of clinical activity, but major uncertainties remain regard

77 Cholesterol level monitoring is a common clinical activity, but the optimal monitoring interval i

78 Clinical activity (by RECIST [Response Evaluation Criter

79 erable safety profile and showed encouraging clinical activity characterised by a high response rate

80 erable safety profile and showed encouraging clinical activity characterised by a high response rate

81 P-CAP showed promising clinical activity compared with CAP in previously treate

82 Evidence of clinical activity (conventional, unconfirmed, or immune-

83 inhibitors which were found to have limited clinical activity due to insufficient kinase inhibitory

84 with sorafenib and bevacizumab has promising clinical activity, especially in patients with ovarian c

85 We recently reported promising clinical activity for a 10-day regimen of decitabine in

86 Moreover, sorafenib may have clinical activity for patients with CLL, particularly th

87 Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies,

88 Closer supervision of residents' clinical activities has been promoted to improve patient

89 Their clinical activity has been correlated with activated T-c

90 Clinical activity has been shown by T cells bearing rece

91 PEG-IFN-alpha-2a resulted in remarkable clinical activity, high rates of molecular response, and

92 olled phase II study was performed assessing clinical activity, immunologic response, and safety foll

93 f leiomyomas as well as to review the actual clinical activities in this field including efficacy and

94 of 11 evaluable subjects but correlated with clinical activity in 4.

95 th mild, reversible toxicity and substantial clinical activity in a heavily pretreated population.

96 factor receptor alpha, RET, and KIT, showed clinical activity in a phase 2 study involving patients

97 s a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elder

98 has been combined with AZA with significant clinical activity in a previous phase I dose finding stu

99 ly PCI-32765) has recently shown encouraging clinical activity in a range of lymphoid malignancies.

100 y overcome resistance and result in relevant clinical activity in a relapsed/refractory setting.

101 is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic

102 ether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL).

103 e vemurafenib has shown limited single-agent clinical activity in BRAF(V600E)-mutant metastatic CRC,

104 potent RAF kinase inhibitor with remarkable clinical activity in BRAF(V600E)-positive melanoma tumou

105 Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC.

106 date, CDK4/6 inhibitors have shown promising clinical activity in breast cancer and lymphomas, but it

107 administration of IL-12p70 has demonstrated clinical activity in cancer patients, but dose-limiting

108 Immunotherapy has clinical activity in certain virally associated cancers.

109 3Kdelta-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and in

110 e immune-modulatory agent lenalidomide shows clinical activity in CLL, but its mechanism is poorly un

111 a selective inhibitor of PI3Kdelta, displays clinical activity in CLL, causing rapid lymph node shrin

112 es of lenalidomide has been reported to have clinical activity in CLL.

113 , CNS-active, ALK inhibitor-showed promising clinical activity in crizotinib-naive and crizotinib-res

114 r immunotherapy has demonstrated significant clinical activity in different cancers.

115 They have also shown promising clinical activity in early-phase clinical studies and ap

116 n important target, and mTOR inhibitors show clinical activity in endometrial cancer.

117 echanism-based target modulation and limited clinical activity in heavily pretreated patients with CL

118 Proteasome inhibitors (PIs) have clinical activity in hematological tumors, and inhibitor

119 Despite unprecedented clinical activity in mantle cell lymphoma (MCL), primary

120 ) inhibitor ibrutinib demonstrated important clinical activity in MCL.

121 Cabozantinib has clinical activity in men with CRPC, including reduction

122 nhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell ca

123 etrexed and gemcitabine resulted in moderate clinical activity in MPM.

124 The proteasome inhibitor bortezomib has clinical activity in multiple myeloma and mantle cell ly

125 ar endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types.

126 fic inhibitor that has shown preclinical and clinical activity in non-Hodgkin lymphoma and chronic ly

127 MEK inhibitors, which have shown clinical activity in NRAS-mutant melanoma, may be effect

128 ibitor veliparib (ABT-888), four agents with clinical activity in ovarian cancer.

129 a covalent pan-HER inhibitor that has shown clinical activity in patients previously treated with ge

130 peutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma.

131 ituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL.

132 le-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC

133 inistration of SGN-30 is safe and has modest clinical activity in patients with CD30(+) tumors.

134 nase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic l

135 Lenalidomide has demonstrated clinical activity in patients with chronic lymphocytic l

136 -199 (venetoclax) has demonstrated promising clinical activity in patients with chronic lymphocytic l

137 ive, and potent ALK inhibitor that has shown clinical activity in patients with crizotinib-naive ALK-

138 this signaling pathway may hold promise for clinical activity in patients with diabetes.

139 demonstrated that inhibitors of FLT3 do have clinical activity in patients with FLT3-mutant AML, alth

140 1 administered as a single-agent had minimal clinical activity in patients with gemcitabine-refractor

141 inase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metasta

142 Dasatinib has significant clinical activity in patients with imatinib resistance.

143 Angiogenesis inhibitors have shown clinical activity in patients with late-stage NSCLC, rai

144 s bioavailable and demonstrated biologic and clinical activity in patients with MDSs and CMML.

145 nged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid can

146 tic index and RAF inhibitors have remarkable clinical activity in patients with melanomas that harbou

147 ression is well-tolerated and shows signs of clinical activity in patients with mesothelioma.

148 IPI-504 has clinical activity in patients with NSCLC, particularly a

149 lymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer.

150 Flavopiridol achieves significant clinical activity in patients with relapsed CLL, includi

151 recently has been shown to have significant clinical activity in patients with relapsed Hodgkin lymp

152 Quizartinib has clinical activity in patients with relapsed/refractory A

153 nation of cixutumumab and temsirolimus shows clinical activity in patients with sarcoma and forms a b

154 le safety profile and evidence of meaningful clinical activity in PD-L1-positive patients with UBC, m

155 The drug seems to mediate some clinical activity in pediatric solid tumors and may work

156 CD19 BiTE((R)) blinatumomab has demonstrated clinical activity in Philadelphia chromosome (Ph)-negati

157 SRC/ABL tyrosine kinase inhibitor (TKI) with clinical activity in Philadelphia chromosome-positive (P

158 mide but has a different safety profile, has clinical activity in relapsed or refractory multiple mye

159 dosing regimen that has achieved significant clinical activity in relapsed, poor-risk chronic lymphoc

160 ori, PF-02341066) has demonstrated promising clinical activity in ROS1 fusion-positive non-small cell

161 hows in vitro activity and early evidence of clinical activity in ROS1-rearranged NSCLC.

162 cific inhibitor of 26S proteasome, has shown clinical activity in several human tumors, including mye

163 target of rapamycin (mTOR) kinase have shown clinical activity in several lymphoma subtypes.

164 There was preliminary evidence of clinical activity in several patients.

165 mab via a stable thioether linker, has shown clinical activity in single-arm studies enrolling patien

166 However, clinical activity in solid tumors has been disappointing

167 versible pan-HER inhibitor, had shown modest clinical activity in squamous cell carcinoma of head and

168 -3-kinase (PI3K)-alpha inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of

169 Entospletinib demonstrates clinical activity in subjects with relapsed or refractor

170 ptosis of ATL cell lines and has significant clinical activity in Tax-driven murine ATL or human pati

171 y indicated that FR104 has potential to show clinical activity in the treatment of immune-mediated di

172 mTOR inhibitors have shown major clinical activity in the treatment of renal cell carcino

173 s in reducing magnetic resonance imaging and clinical activity in therapeutic trials indicates that B

174 A phase II trial was performed to determine clinical activity in this patient cohort.

175 how for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset o

176 Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF

177 is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-res

178 or receptor, c-KIT, and PDGFR, and has shown clinical activity in various solid tumors.

179 We recorded some evidence of clinical activity in various solid tumours, with partial

180 ther improved CD20 antibodies with promising clinical activity, including ofatumumab and GA-101, are

181 d B-cell lymphoma and demonstrates promising clinical activity, including patients who were refractor

182 s for whom the targets were achieved, for 48 clinical activity indicators during the first 3 years of

183 High clinical activity indices (CAI) and sigmoidoscopy scores

184 Clinical coding is the translation of clinical activity into a coded language.

185 ical development and despite promising early clinical activity, intrinsic resistance is frequent amon

186 The ability to predict future clinical activity is uncertain, likely limited by presen

187 squinimod and offer a perspective on how its clinical activity might be leveraged in combination with

188 Purpose The clinical activity observed in a phase I dose-escalation

189 The degree of clinical activity observed supports additional studies t

190 eatment of nonpromyelocytic AML with limited clinical activity observed.

191 Prior work showed immunologic and clinical activity of 6MHP alone.

192 These results are the first to establish the clinical activity of a CD22-CAR in B-ALL, including leuk

193 We have previously shown clinical activity of a mammalian target of rapamycin (mT

194 he objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humaniz

195 ) and objective response rate suggested some clinical activity of bevacizumab and erlotinib.

196 1-807R cells, suggesting potentially broader clinical activity of BMS-754807.

197 These data provide an explanation for the clinical activity of CAL-101, and a roadmap for future t

198 irculating and image-derived biomarkers, and clinical activity of combination aflibercept and docetax

199 Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK

200 -arm, phase II study assessed the safety and clinical activity of dabrafenib in BRAF(V600E/K) mutatio

201 We did a trial to assess the clinical activity of dabrafenib in patients with advance

202 demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML a

203 l evidence, including the lack of convincing clinical activity of early FLT3 inhibitors, suggests tha

204 ic and pharmacodynamic profiles, safety, and clinical activity of enasidenib in patients with mutant-

205 This open-label, phase II study assessed the clinical activity of everolimus in patients with metasta

206 Considering the disappointing clinical activity of HSP90 inhibitors in other contexts,

207 provides additional evidence for the durable clinical activity of immune checkpoint inhibitors in the

208 im of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy

209 redictive value of beta3T in differentiating clinical activity of ixabepilone- or paclitaxel-containi

210 s concept recently gained momentum after the clinical activity of kinase inhibitors that target BCR s

211 okinetics, pharmacodynamics, and preliminary clinical activity of lapatinib and docetaxel in patients

212 ndings provide a rationale for exploring the clinical activity of LBH589 in the treatment of patients

213 These findings have implications for the clinical activity of lenalidomide and related compounds,

214 ansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853)

215 However, the clinical activity of NAMPT inhibitors has proven limited

216 te safety, pharmacokinetics, and preliminary clinical activity of OTX015.

217 This is the first demonstration of clinical activity of PD-1 blockade in DLBCL.

218 We conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti-programmed d

219 We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or

220 port safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted alphaDC1-based va

221 s could be a new way to detect a significant clinical activity of proteasome inhibitors in AML patien

222 Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RI

223 the biodistribution, dosimetry, safety, and clinical activity of radretumab.

224 ective exploratory analysis investigated the clinical activity of regorafenib in biomarker subgroups

225 The clinical activity of sirolimus in PEComa additionally st

226 We aimed to assess the safety and clinical activity of subcutaneously given guadecitabine

227 The clinical activity of sunitinib after imatinib failure is

228 The lack of clinical activity of systemically given oncolytic Ad dem

229 r (CRPC); however, mechanisms underlying the clinical activity of taxanes are poorly understood.

230 lon inhibitor, which may in part explain the clinical activity of TGR-1202 in aggressive lymphoma not

231 of the 1000 mg dose in treatment group A and clinical activity of the 2000 mg dose established in chr

232 of this study was to explore the safety and clinical activity of the combination of brentuximab vedo

233 , 1.59 to 5.26; P<0.001) with no increase in clinical activity of the hypereosinophilic syndrome.

234 the treatment of cancer, as evidenced by the clinical activity of the recently approved ADCs, brentux

235 OTR), pharmacokinetics (PK), and preliminary clinical activity of this combination in patients with E

236 This study demonstrates the tolerability and clinical activity of this combination with quicker time

237 ssibly explaining some of the characteristic clinical activity of this new targeted agent.

238 We report herein on the preclinical and clinical activity of this targeted strategy in aggressiv

239 Our data show substantial clinical activity of trametinib in melanoma and suggest

240 accines, with a focus on the preclinical and clinical activities on the MV/Schw-based candidate, whic

241 stoma, although cediranib showed evidence of clinical activity on some secondary end points including

242 ut do not have any relevance with respect to clinical activity or prognosis.

243 ed by considerable favorable preclinical and clinical activities over the past several years and culm

244 lt, PI3K pathway inhibitors may have limited clinical activity overall if used as single agents.

245 CCR4, is well tolerated and has significant clinical activity (overall response rate 36.8%, median d

246 The observed clinical activity (partial response and prolonged progre

247 Among biomarkers to assess clinical activity, pentraxin-3 is perhaps the most promi

248 and toxicity; secondary end points assessed clinical activity per Response Evaluation Criteria in So

249 lung cancer (NSCLC) by the FDA, demonstrates clinical activity primarily in patients with tumors that

250 The observed safety/tolerability and clinical activity profile of sifalimumab support its con

251 cted by comparing men and women with similar clinical activity, renumeration was still lower for wome

252 lanoma but did not demonstrate the promising clinical activity reported with vaccine and high-dose IL

253 The clinical activity score (CAS) included 10 items of ophth

254 ogic correlation was made by determining the clinical activity score (CAS) of each patient with TED.

255 sease assessment include the Indian Takayasu Clinical Activity Score (ITAS2010), which incorporates c

256 ed as a reduction of 2 points or more in the Clinical Activity Score (scores range from 0 to 7, with

257 ontinuous variables, included proptosis, the Clinical Activity Score, and results on the Graves' opht

258 e than placebo in reducing proptosis and the Clinical Activity Score.

259 Clinical activity seems similar to standard high-dose al

260 Its clinical activity should be further assessed in NHL.

261 Its impressive clinical activity shown in a phase IB trial led to accel

262 No statistically significant differences in clinical activity (SLEDAI and British Isles Lupus Assess

263 ce, with equity in opportunity and parity in clinical activity standing to benefit the specialty.

264 k proposes epigenetic discrimination between clinical activity states, and reveals T-cell-related bio

265 clinical results, along with early promising clinical activity, suggest that CC-115 may be developed

266 -brain barrier by AZD3759, and its promising clinical activity, support further assessment of this co

267 We report clinical activity, survival, and long-term safety in pat

268 had a manageable safety profile and provided clinical activity that appears to be distinct from that

269 Dasatinib as a single agent had modest clinical activity that was lower than that generally obs

270 inib's inhibition of the expected target and clinical activity warrants its further development as a

271 Clinical activity was assessed before and four weeks fol

272 Clinical activity was assessed by the Rachmilewitz Index

273 Clinical activity was demonstrated in neuroendocrine, co

274 to trastuzumab, the safety was improved and clinical activity was demonstrated.

275 In the MAGE-A3+AS15 arm, clinical activity was higher and the immune response mor

276 On multivariate analysis, increased clinical activity was inversely associated with both sal

277 Evidence of clinical activity was noted both in patients with PD-L1-

278 Some suggestion of clinical activity was noted in 23 (49%) of 47 patients w

279 ab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pa

280 Minimal clinical activity was observed as sequential therapy in

281 Significant clinical activity was observed in BRAF-inhibitor-naive p

282 oup of patients with ASS1-deficient cancers, clinical activity was observed in patients with poor-pro

283 Clinical activity was observed independent of PIK3CA mut

284 Otlertuzumab was well tolerated, and modest clinical activity was observed.

285 Clinical activity was seen in this phase I drug combinat

286 Other signs of clinical activity were also observed, with 11 patients (

287 Safety and clinical activity were assessed in all patients who rece

288 ous and current therapy, laboratory data and clinical activity were recorded at the time of TDM.

289 Pathway inhibition and clinical activity were seen, with 21 (10%) objective res

290 IK3CA/PIK3R1 mutation did not correlate with clinical activity, whereas RAS/RAF pathway mutations did

291 The findings of clinical activity will require validation in a phase 2 t

292 Axitinib shows clinical activity with a manageable safety profile in tr

293 chieves early steady-state concentration and clinical activity with an acceptable safety profile in r

294 Clinical activity with anti-CTLA-4 monoclonal antibodies

295 herapy with bevacizumab and erlotinib showed clinical activity with infrequent grade 3 and 4 adverse

296 Osimertinib showed clinical activity with manageable side-effects in patien

297 e times per week, has promising single-agent clinical activity with manageable toxicity in patients w

298 Despite measurable clinical activity with new targeted therapies, many pati

299 tylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses

300 Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in